APP-FUBINACA

Add links
Source: Wikipedia, the free encyclopedia.
APP-FUBINACA
Legal status
Legal status
Identifiers
  • N-(1-amino-3-phenyl-1-oxopropan-2-yl)-1-[(4-fluorophenyl)methyl]-1H-indazole-3-carboxamide
JSmol)
  • O=C(N[C@H](C(N)=O)CC1=CC=CC=C1)C2=NN(CC3=CC=C(F)C=C3)C4=C2C=CC=C4
  • InChI=1S/C24H21FN4O2/c25-18-12-10-17(11-13-18)15-29-21-9-5-4-8-19(21)22(28-29)24(31)27-20(23(26)30)14-16-6-2-1-3-7-16/h1-13,20H,14-15H2,(H2,26,30)(H,27,31)/t20-/m0/s1
  • Key:TZXBEYFALIFOAG-FQEVSTJZSA-N

APP-FUBINACA is an

CB1 receptor, with a Ki of 708 nM, while its EC50 was not tested.[2] It contains a phenylalanine
amino acid residue in its structure. [3]

Legality

Sweden's public health agency suggested to classify APP-FUBINACA as hazardous substance on March 24, 2015.[4]

See also

References

  1. ^ "APP-FUBINACA". Cayman Chemical. Retrieved 15 July 2015.
  2. ^ WO 2009106982, Buchler IP, Hayes MJ, Hedge SG, Hockerman SL, Jones DL, Kortum SW, Rico JG, Tenbrink RE, Wu KK, "Indazole derivatives", published 3 September 2009, assigned to Pfizer Inc 
  3. ^ Evelyn, Alex. "HHC (Hexahydrocannabinol)". Retrieved 19 December 2021.
  4. ^ "Fler ämnen föreslås bli klassade som narkotika eller hälsofarlig vara". Folkhälsomyndigheten. Retrieved 16 July 2015.
  5. S2CID 227246346
    .
Retrieved from "https://en.wikipedia.org/w/index.php?title=APP-FUBINACA&oldid=1205103546"